X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will advance phase 1/2a clinical study of AXT107 (gersizangitide), which inhibits pro-angiogenic VEGFR2 and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.
Lead Product(s): Gersizangitide
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 26, 2023
Details:
AXT107 is an investigational drug candidate that inhibits VEGF-A and VEGF-C and activates Tie2. With its novel mechanisms of action, AXT107 has the potential to be a standard of care monotherapy.
Lead Product(s): Gersizangitide
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
Proceeds will be used to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials.
Lead Product(s): Gersizangitide
Therapeutic Area: Ophthalmology Product Name: AXT107
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund
Deal Size: Undisclosed Upfront Cash: $35.0 million
Deal Type: Series A Financing June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
